Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium
December 11, 2024 07:05 ET | Source: Celcuity Inc. Median overall survival…
PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024
Multiple well-tolerated doses with pharmacodynamic activity were identified and will be included…
Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024
Multiple well-tolerated doses with pharmacodynamic activity were identified and will be included…
IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001
Based on more than six months of additional monitoring, data show continued…
Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia
Phase 1 data from the CAReS trial showed an attractive safety profile…
Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
December 08, 2024 12:00 ET | Source: Cogent Biosciences, Inc. 52% ORR…
Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for -Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
Treatment effects sustained through long-term follow-up of beyond 10 years in the…
MiNA Therapeutics Presents New Pre-Clinical Data from Lead Sickle Cell Disease Program at the American Society of Hematology Annual Meeting
MTL-HBG drug candidate demonstrated best-in-class activity and safety in pre-clinical models Data…
Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting
December 07, 2024 12:00 ET | Source: Y-mAbs Therapeutics, Inc. NEW YORK,…
Merus Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC
Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing HNSCC ongoing…